BiPAP联合氧气驱动雾化吸入布地奈德可改善慢性阻塞性肺疾病急性期合并2型糖尿病患者的临床指标

BiPAP combined with oxygen-driven budesonide nebulization improves clinical indicators

摘要:

目的 观察双水平气道正压通气（BiPAP）联合氧气驱动雾化吸入布地奈德治疗慢性阻塞性肺疾病急 性期（AECOPD）合并2型糖尿病（T2DM）患者的疗效。方法 110例AECOPD合并T2DM患者随机采用BiPAP（对 照组）或BiPAP联合氧气驱动雾化吸入布地奈德（观察组）治疗，疗程均为7 d。比较两组的疗效、不良反应及血气、 生命体征、炎症反应、应激反应、糖代谢、肺功能指标。结果 与对照组相比，观察组治疗后 PaCO2、心率、呼吸、 hs-CRP、WBC、MDA、DI均明显降低，而PaO2、SOD、FEV1%和FEV1/FVC明显升高（P < 0.01或0.05）。观察组疗效 优于对照组（P < 0.05）。结论 BiPAP联合氧气驱动雾化吸入布地奈德可改善AECOPD合并T2DM患者的血气、生 命体征、炎症反应、应激反应和肺功能指标，提高疗效。

Abstract:

Objective To observe the efficacy of bi-level positive airway pressure ventilator (BiPAP) and oxygendriven aerosol inhalation of budesonide in patients with acute exacerbation of chronic obstructive pulmonary diseases (AECOPD) and type 2 diabetes mellitus (T2DM). Methods A total of 110 AECOPD patients with T2DM were randomly treated with BiPAP (control group) or BiPAP plus oxygen-driven budesonide nebulization (observation group) for 7 days. Clinical efficacy, adverse reactions, blood gas, vital signs, inflammatory response, stress response, glucose metabolism, and pulmonary function indexes were compared between two groups. Results Compared with control group, PaCO2, heart rate, respiration, hs-CRP, WBC, MDA, DI were significantly decreased, while PaO2, SOD, FEV1% and FEV1/FVC increased in observation group (P < 0.01 or 0.05). The curative effect was better in observation group than in control group (P < 0.05). Conclusion BiPAP combined with oxygen-driven budesonide nebulization can improve the curative effect as well as blood gas, vital signs, inflammatory response, stress response and pulmonary function in patients with AECOPD and T2DM.